Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/40465
Title: | Osteoporosis treatment: A missed opportunity. | Authors: | Milat F.;Ebeling P.R. | Institution: | (Milat, Ebeling) Monash University, Melbourne, VIC, Australia (Milat) Monash Medical Centre, Melbourne, VIC, Australia | Issue Date: | 29-Aug-2016 | Copyright year: | 2016 | Publisher: | Australasian Medical Publishing Co. Ltd (E-mail: ampco@ampco.com.au) | Place of publication: | Australia | Publication information: | Medical Journal of Australia. 205 (4) (pp 185-190), 2016. Date of Publication: 15 Aug 2016. | Journal: | Medical Journal of Australia | Abstract: | Osteoporosis affects 1.2 million Australians and, in 2012, fractures due to osteoporosis and osteopenia in Australians aged over 50 years cost $2.75 billion. Even minor minimal trauma fractures are associated with increased morbidity and mortality. Despite increasing therapeutic options for managing osteoporosis, fewer than 20% of patients with a minimal trauma fracture are treated or investigated for osteoporosis, so undertreatment is extremely common. Fracture risk assessment is important for selecting patients who require specific anti-osteoporosis therapy. Post-menopausal osteoporosis is frequently due to an imbalance in bone remodelling, with bone resorption exceeding bone formation. Antiresorptive drugs reduce the number, activity and lifespan of osteoclasts, and include bisphosphonates, oestrogen, selective oestrogen receptor-modulating drugs, strontium ranelate, and the human monoclonal antibody denosumab. Teriparatide is the only anabolic agent currently available that stimulates osteoblast recruitment and activity; its antifracture efficacy for non-vertebral fractures increases with the duration of therapy for up to 2 years when it is associated with persisting increases in bone formation rate at the tissue level. Newer anabolic agents are imminent and include an analogue of parathyroid hormone-related protein, abaloparatide, and a humanised monoclonal antibody to an inhibitor of bone formation, romosozumab. Selection of anti-osteoporosis therapy should be individualised to patients, and the duration of bisphosphonate therapy has been covered in recent guidelines. The benefits of treatment far outweigh any risks associated with long term treatment. General practitioners need to take up the challenge imposed by osteoporosis and become champions of change to close the evidenceetreatment gap.Copyright © 2016 AMPCo Pty Ltd. Produced with Elsevier B.V. All rights reserved. | DOI: | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.5694/mja16.00568 | PubMed URL: | 27510350 [http://www.ncbi.nlm.nih.gov/pubmed/?term=27510350] | ISSN: | 0025-729X | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/40465 | Type: | Article | Subjects: | insulin dependent diabetes mellitus jaw osteonecrosis lifestyle modification *osteoporosis/dt [Drug Therapy] *osteoporosis/ep [Epidemiology] *osteoporosis/pc [Prevention] osteoporosis/dt [Drug Therapy] postmenopause osteoporosis practice guideline pregnant woman randomized controlled trial (topic) resistance training risk assessment smoking cessation treatment duration abaloparatide/dt [Drug Therapy] alendronic acid/dt [Drug Therapy] anabolic agent/dt [Drug Therapy] bisphosphonic acid derivative/dt [Drug Therapy] calcium/dt [Drug Therapy] denosumab/dt [Drug Therapy] estrogen/dt [Drug Therapy] odanacatib/dt [Drug Therapy] parathyroid hormone[1-34]/dt [Drug Therapy] progesterone/dt [Drug Therapy] raloxifene/dt [Drug Therapy] romosozumab/dt [Drug Therapy] selective estrogen receptor modulator/dt [Drug Therapy] strontium ranelate/dt [Drug Therapy] vitamin D/dt [Drug Therapy] fracture alcohol abstinence article Australia bone density bone remodeling calcium intake chronic kidney disease clinical trial (topic) dietary reference intake drug efficacy drug mechanism falling femur fracture hormone substitution human femur fracture fracture hormone substitution human insulin dependent diabetes mellitus jaw osteonecrosis lifestyle modification *osteoporosis / *drug therapy / *epidemiology / *prevention osteoporosis / drug therapy postmenopause osteoporosis practice guideline pregnant woman randomized controlled trial (topic) resistance training risk assessment smoking cessation treatment duration bone density Article alcohol abstinence Australia bone remodeling calcium intake chronic kidney disease clinical trial (topic) dietary reference intake drug efficacy drug mechanism falling |
Appears in Collections: | Articles |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.